Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
Authors
Keywords
-
Journal
MOLECULES
Volume 24, Issue 11, Pages 2152
Publisher
MDPI AG
Online
2019-06-07
DOI
10.3390/molecules24112152
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Flubendazole induces mitotic catastrophe and apoptosis in melanoma cells
- (2018) K. Čáňová et al. TOXICOLOGY IN VITRO
- Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways
- (2018) Nilambra Dogra et al. Scientific Reports
- A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein
- (2017) Georgios Valianatos et al. PLoS One
- Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer
- (2017) Farhad Ghasemi et al. Oncotarget
- The Roles of MDM2 and MDMX in Cancer
- (2016) Orit Karni-Schmidt et al. Annual Review of Pathology-Mechanisms of Disease
- Flubendazole induces mitotic catastrophe and senescence in colon cancer cellsin vitro
- (2016) Věra Králová et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Albendazole as a promising molecule for tumor control
- (2016) L.S.E.P.W. Castro et al. Redox Biology
- Potential Anti-cancer Drugs Commonly Used for Other Indications
- (2015) Veronika Hanusova et al. CURRENT CANCER DRUG TARGETS
- Exploration of Structure-Based on Imidazole Core as Antibacterial Agents
- (2013) Yong-Tao Duan et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
- (2013) Brijal M. Desai et al. PLoS One
- Impairment of the Ubiquitin-Proteasome Pathway by MethylN-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells
- (2012) Nilambra Dogra et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- MDM4 is a key therapeutic target in cutaneous melanoma
- (2012) Agnieszka Gembarska et al. NATURE MEDICINE
- Benzo[c]phenanthridine alkaloids exhibit strong anti-proliferative activity in malignant melanoma cells regardless of their p53 status
- (2011) Jindřiška Hammerová et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Albendazole sensitizes cancer cells to ionizing radiation
- (2011) Kirtesh Patel et al. Radiation Oncology
- Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis
- (2010) Mohammad H. Pourgholami et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Potent inhibition of tumoral hypoxia-inducible factor 1α by albendazole
- (2010) Mohammad H Pourgholami et al. BMC CANCER
- Dibenzocyclooctadiene lignans overcome drug resistance in lung cancer cells – Study of structure–activity relationship
- (2009) I. Slaninová et al. TOXICOLOGY IN VITRO
- Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells
- (2008) N. Doudican et al. MOLECULAR CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More